New Risk • May 17
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$26m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$26m free cash flow). Earnings have declined by 39% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 24x increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (15% average weekly change). Market cap is less than US$100m (US$44.8m market cap). Announcement • Mar 10
SRx Health Solutions, Inc. Launches EventHorizonIQ Subscription SRx Health Solutions Inc. and EMJ Crypto Technologies announced the launch of the EventHorizonIQ subscription, a premium offering that brings institutional-grade cross-asset regime intelligence to market participants seeking deeper insights into evolving macro, crypto, and behavioral market regimes. EventHorizonIQ is a cross-asset regime intelligence system that continuously monitors a broad set of quantitative sensors — spanning macroeconomic indicators (e.g., VIX, Treasury yields, Fed policy), crypto-native data (e.g., BTC dominance, stablecoin flows), and behavioral signals — to deliver a real-time classification of market state changes. All regime states are timestamped and recorded to an immutable ledger, providing a verifiable, auditable record of market conditions that is free from edits or retrospective alteration. EventHorizonIQ Subscription Highlights: Comprehensive Sensor Coverage: Subscribers gain expanded access to sophisticated regime signals derived from 22+ sensors covering macro, crypto, and behavioral domains. Immutable Intelligence Ledger: All observed regime states are logged to an uneditable, timestamped ledger — preserving what was recorded, when it was recorded — for independent verification. Proprietary Composite Signals: Premium tiers include advanced composite indicators and numerical scores enabling deeper trend analysis and sector-specific insights. Subscription Tiers for All Users: The free tier provides access to full sensor history and states; the subscription level unlocks enhanced analytics, priority reporting, and customizable alerts. Unlike prediction markets or traditional forecasting tools, EventHorizonIQ is not designed to speculate on future price moves or generate trading recommendations. Instead, the platform focuses on observing, classifying, and recording prevailing market regimes — equipping subscribers with timely diagnostic intelligence to inform risk assessments and capital allocation decisions. Announcement • Feb 21
SRx Health Solutions Announces Receipt of Warning Letter from NYSE American SRx Health Solutions Inc. (the "Company") announced that on February 18, 2026, it received a public warning letter (the "Letter") from the NYSE Regulation Staff of the New York Stock Exchange (the "Exchange") notifying the Company that it failed to comply with Sections 301 and 713 of the NYSE American LLC Company Guide (the "Company Guide"). The Letter relates to the issuance of approximately 7.5 million shares (the "Subject Shares") of the Company's common stock, par value $0.001 per share (the "Common Stock"), between December 31, 2025 and January 23, 2026, upon conversion of certain shares of the Company's Series A Convertible Preferred Stock, par value $0.001 per share (the "Preferred Shares"). The Preferred Shares were issued pursuant to a Securities Purchase Agreement, dated October 27, 2025, by and among the Company and certain investors (the "Agreement"). The Agreement and the Preferred Shares are described in the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission (the "SEC") on October 31, 2025. Specifically, the Letter states that the Company failed to file an application to obtain the Exchange's listing approval for the issuance of additional shares of the Common Stock as required under Section 301 of the Company Guide and failed to obtain stockholder approval of an issuance that exceeded 20% of the Common Stock outstanding, as required under Section 713 of the Company Guide. The Company filed an application to obtain the Exchange's listing approval for the issuance of the Common Stock issuable upon conversion of the Preferred Shares on December 12, 2025. At the time of such filing, the conditions precedent to the conversion of the Preferred Shares under the Agreement had not been met and no shares of Common Stock had been issued in connection therewith. The Company obtained stockholder approval of the issuance of the Preferred Shares, and the issuance of the Common Stock upon the conversion thereof, including the potential for such issuance to exceed 20% of the Common Stock then-outstanding, by written consent of the stockholders on October 8, 2025. Such stockholder actions taken by written consent are described in the Company's Definitive Schedule 14C filed with the SEC on October 20, 2025. The Exchange has advised the Company that such stockholder approval was deficient under the Exchange's unpublished internal guidance on generic proxy proposals, which led to the violations set in the Letter. As of the date of this Current Report, all of the Preferred Shares have been either converted into Common Stock or redeemed by the Company, and no Preferred Shares are outstanding. Such redemption of Preferred Shares is described in the Company's Current Report on Form 8-K filed with the SEC on February 12, 2026. 
